Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1445]
News [2210]
Articles [39]
Editorials [5]
Conferences [150]
elearning [0]
FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation
FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation
Study reveals significant global disparities in cancer care across different countries
Study reveals significant global disparities in cancer care across different countries
FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukaemia
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukaemia
Significant worldwide disparities in availability and timeliness of new cancer drugs
Significant worldwide disparities in availability and timeliness of new cancer drugs
FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
IAEA, Honduras and Japan join forces to strengthen Cancer Care Access through Rays of Hope
IAEA, Honduras and Japan join forces to strengthen Cancer Care Access through Rays of Hope
Nearly 200 potential mammary carcinogens found in food contact materials: new study highlights regulatory shortcomings
Nearly 200 potential mammary carcinogens found in food contact materials: new study highlights regulatory...
WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation